Biomarkers in barrett esophagus

Kausilia Krishnawatie Krishnadath, Brian J. Reid, Kenneth Ke Ning Wang

Research output: Contribution to journalArticlepeer-review


Barrett esophagus is a premalignant condition that may progress to adenocarcinoma. The risk of developing cancer has been estimated to be approximately 1 in 250 patient-years of observation; however, there appear to be subsets of patients at much higher risk. Risk stratification has previously been determined by histological identification of dysplasia. Several new biomarkers are being tested to help clinicians better determine the risk of cancer development. Although none of these biomarkers has been proven in a prospective study to predict the onset of cancer, they have been correlated with cancer development. Most of these are factors that have been associated with cancer development in other organs. These include assessment of cell proliferation, expression of cyclooxygenase 2, growth factors and oncogenes, secretory factors, cell cycle proteins, adhesion molecules, and aneuploidy and other genetic abnormalities. In addition to their role as potential cancer biomarkers, these factors have increasingly been reported as surrogate markers to monitor the effectiveness of conservative treatments for Barrett esophagus. In this article, biological markers are reviewed for their relevance in Barrett esophagus. Although most biological markers need to be evaluated further and, for most, prospective follow-up studies are lacking, at present abnormal ploidy status, PI 6 and P53 gene abnormalities, or allelic losses are the most extensively documented.

Original languageEnglish (US)
Pages (from-to)433-437
Number of pages5
JournalMayo Clinic Proceedings
Issue number4
StatePublished - 2001

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Biomarkers in barrett esophagus'. Together they form a unique fingerprint.

Cite this